DEA Issues Notice of Intent to Temporarily Place 7-Hydroxymitragynine in Schedule I of Controlled Substances Act

The Drug Enforcement Administration (DEA) has announced its intent to temporarily classify 7-hydroxymitragynine, a substance found in kratom, as a Schedule I controlled substance. This action is based on findings that the substance poses an imminent hazard to public safety, following FDA warning letters issued in 2025 regarding its unlawful use in drugs, dietary supplements, and food. The temporary scheduling order is expected to be published in the Federal Register on or after August 5, 2026, and will remain in effect for two years, with a possible extension.

Context

7-hydroxymitragynine is a compound derived from kratom, a plant that has gained popularity for its psychoactive effects. The FDA has previously issued warnings about the substance, citing its potential for misuse and health risks. The DEA's action follows increasing scrutiny of kratom and similar substances as part of a broader initiative to regulate drugs that may pose dangers to consumers.

Why it matters

The DEA's decision to classify 7-hydroxymitragynine as a Schedule I substance highlights growing concerns about public health and safety regarding certain substances. This classification may impact the availability of kratom and related products, affecting users and the market. It also reflects ongoing efforts by regulatory agencies to address potential risks associated with emerging drugs.

Implications

The scheduling of 7-hydroxymitragynine may lead to reduced access for consumers who use kratom for pain relief or other purposes. It could also affect businesses involved in the production and sale of kratom products, potentially leading to economic repercussions. Additionally, this decision may set a precedent for how other similar substances are regulated in the future.

What to watch

The temporary scheduling order is anticipated to be published in the Federal Register after August 5, 2026, marking the start of a two-year classification period. Stakeholders, including manufacturers and consumers, will likely respond with legal or legislative actions. Observers should monitor public health discussions and any emerging research on the effects of 7-hydroxymitragynine during this period.